title: Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats.
abstract: Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor used in treatment of hypercholesterolemia and prevention of coronary heart disease. The aim of this study is to investigate the antihyperalgesic and anti-inflammatory effects of atorvastatin (3, 10, and 30 mg/kg by oral gavages for 14 days) in chronic constriction injury (CCI) model of neuropathic pain in rats. CCI caused significant increase in tumor necrosis factor-α, interleukin 1 beta, prostaglandin E2, along with matrix metalloproteases (MMP-2) and nerve growth factor (NGF) levels in sciatic nerve and spinal cord concomitant with mechanical and thermal hyperalgesia, which were significantly reduced by oral administration of atorvastatin for 14 days as compared to CCI rats. Our study demonstrated that atorvastatin attenuates neuropathic pain through inhibition of cytokines, MMP-2, and NGF in sciatic nerve and spinal cord suggesting that atorvastatin could be an additional therapeutic strategy in management of neuropathic pain.
authors.affiliation: Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, 243 122, India.
authors.forename: Nitya N
authors.initials: NN
authors.lastname: Pathak
authors.forename: Venkanna
authors.initials: V
authors.lastname: Balaganur
authors.forename: Madhu C
authors.initials: MC
authors.lastname: Lingaraju
authors.forename: Amar S
authors.initials: AS
authors.lastname: More
authors.forename: Vinay
authors.initials: V
authors.lastname: Kant
authors.forename: Dhirendra
authors.initials: D
authors.lastname: Kumar
authors.forename: Dinesh
authors.initials: D
authors.lastname: Kumar
authors.forename: Surendra Kumar
authors.initials: SK
authors.lastname: Tandan
mesh_terms: D000698:Analgesia; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D003250:Constriction; D015232:Dinoprostone / Q000096:biosynthesis; D004195:Disease Models, Animal; D006538:Heptanoic Acids / Q000627:therapeutic use*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000096:biosynthesis; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis; D020932:Nerve Growth Factor / Q000096:biosynthesis; D009437:Neuralgia / Q000188:drug therapy*; D010147:Pain Measurement; D011758:Pyrroles / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000378:metabolism*; D013116:Spinal Cord / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000893:Anti-Inflammatory Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D053583:Interleukin-1beta; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; D020932:Nerve Growth Factor; D000069059:Atorvastatin; D020778:Matrix Metalloproteinase 2; D015232:Dinoprostone